Hematopoietic stem cell transplantation for multiple sclerosis: no inflammation, no response

IF 4.5 2区 医学 Q1 CLINICAL NEUROLOGY
Richard K. Burt, Tobias Alexander, the EBMT Autoimmune Diseases Working Party (ADWP)
{"title":"Hematopoietic stem cell transplantation for multiple sclerosis: no inflammation, no response","authors":"Richard K. Burt,&nbsp;Tobias Alexander,&nbsp;the EBMT Autoimmune Diseases Working Party (ADWP)","doi":"10.1111/ene.16565","DOIUrl":null,"url":null,"abstract":"<p>In this edition of the <i>European Journal of Neurology</i>, Braun et al. report results from a systematic literature review of publications reporting on autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) undergoing progressive neurological decline in baseline without clinical relapses or decline between clinical relapses. They compared 665 patients with progressive multiple sclerosis (PMS) of which 74 were primary progressive MS (PPMS) defined as PMS from diagnosis and 591 with secondary progressive MS (SPMS) defined as PMS after an initial relapsing–remitting course. As controls they used 647 patients with RRMS defined as a relapsing–remitting course with stable neurological disability between relapses [<span>1</span>].</p><p>There are 16 disease modifying therapies (DMTs) approved by the Food and Drug Administration for RRMS. The effectiveness of DMTs for PMS is questionable or at best less clear. Multiple studies have demonstrated superiority of HSCT for RRMS including a large meta-analysis of 4831 patients [<span>2</span>] and a phase III randomized trial [<span>3</span>]. Because an effective therapy is needed for PMS, Braun et al. summarized the published outcome of HSCT for PMS. They found highly variable results in PMS patients in terms of achieving progression-free survival and no evidence of disease activity (NEDA-3), suggesting that HSCT does not halt progression in this patient cohort but may provide clinical benefit in selected patients.</p><p>RRMS is a dynamic and repetitive immune mediated breakdown in the blood–brain barrier, extravasation of immune cells, and macrophage stripping of myelin followed healing of the blood–brain barrier, remyelination and repair [<span>4</span>]. Neuronal damage starts during RRMS and becomes the predominate pathophysiology during SPMS [<span>5</span>]. PPMS is predominately neuronal degenerative from onset [<span>6</span>]. For this reason, immune based therapies including all DMTs and autologous HSCT are most effective in RRMS but of limited value for PMS (PPMS or SPMS) [<span>6</span>]. During the transition from predominately inflammatory RRMS into late SPMS, patients transition through a stage of SPMS with residual smoldering inflammation [<span>7</span>]. It is during this stage that immune based therapies such as HSCT are still of benefit, albeit to a lesser amount. On this background, recent guidelines and recommendations from the European Group for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and the International Society for Cellular Therapy (ISCT) (JACIE) suggest HSCT as standard indication in patients with active relapsing–remitting MS failing DMTs, and a clinical option in patients with progressive MS with active inflammatory component, but generally not in patients with progressive MS without active inflammatory component [<span>8</span>].</p><p>Identifying subsets of PMS that may still benefit from HSCT is essential. Two such subsets are active SPMS and potentially those with progression independent of relapse activity (PIRA). SPMS may be divided into active SPMS and non-active SPMS [<span>9</span>]. Non-active SPMS is quiescent in terms of relapses and new magnetic resonance imaging (MRI) lesions [<span>8</span>]. Active SPMS manifests a clinical relapse or a new MRI lesion over the prior year [<span>8</span>]. Using a non-myeloablative HSCT regimen of cyclophosphamide and anti-thymocyte globulin (ATG), the neurological disability of patients with active SPMS improved [<span>10</span>]. RRMS and active SPMS had a sustained mean decline in Expanded Disability Status Scale of &gt;1.0 and &gt;0.5 points, respectively, after HSCT [<span>9</span>]. Non-active SPMS did not improve [<span>10</span>]. The extent to which active neuronal inflammation at baseline had an influence on the reported results of Braun et al. in PMS patients remains unclear, as no data on this subject were included. Nevertheless, the available data demonstrating that PPMS patients benefited less than SPMS and particularly RRMS patients clearly indicate that the less inflammation the lower the response to HSCT.</p><p>Patients treated with anti-B cell monotherapy may have slow silent accumulation of disability without clinical relapses or MRI changes, a phenomenon termed PIRA [<span>11</span>]. To ensure that MRI imaging was included in truly defining PIRA, recently the term PIRMA (progression independent of relapse and MRI activity) was introduced [<span>12</span>]. Relapse-independent accumulation of disability has been documented for patients on natalizumab [<span>13</span>]. Recently more specialized MRI analysis has documented persistent paramagnetic rim lesions in patients on ocrelizumab [<span>14</span>]. Such studies suggest that PIRMA arises from incomplete treatment of smoldering inflammation not evident by gross clinical relapse or on routine MRI. MRI paramagnetic rim lesions are associated with PIRMA and arise from and are consistent with persistent low-grade inflammation, free radical generation, and iron deposition in activated microglia and immune cells located on the periphery of chronic active lesions.</p><p>Why is PIRMA so prevalent for patients on anti-CD20 B cell monoclonal therapy? B cells play a role in MS and traffic into and out of acute lesions and are only a small percentage of immune cells within chronic active lesions [<span>15</span>]. It is therefore possible that B cell directed therapies do not cover smoldering low-grade T cell mediated inflammation. Elimination of B cell activity but unchecked T cell reactivity may lead to no noticeable clinical attacks and no new MRI lesions on routine MRI but slow progression of disability, that is, PIRMA. Recently we have performed HSCT with a non-myeloablative regimen using cyclophosphamide and ATG in several patients on anti-CD20 monoclonal antibody therapy with PIRMA. All had improvement in Expanded Disability Status Scale and reversal of symptoms after HSCT (unpublished), suggesting that the mechanisms of HSCT would go beyond a single cell line effect (T or B cell directed).</p><p>In conclusion, the report by Braun et al. confirms previous findings demonstrating better outcomes in RRMS compared to SPMS and PPMS patients and suggests that central nervous system inflammation is a predictor for response. While HSCT is usually ineffective in late SPMS (non-active SPMS) or PPMS, there is early evidence that some types of PMS such as active SPMS and PIRMA while on anti-CD20 B cell therapy do benefit from HSCT probably because of continued smoldering inflammation. Further studies are required in MS to clearly demonstrate the efficacy of HSCT in reducing PIRMA, and these investigations should use harmonized definitions of PIRMA [<span>16</span>]. These aspects should be considered when selecting patients for HSCT in addition to failure of available DMTs.</p><p><b>Richard K. Burt:</b> Writing – original draft. <b>Tobias Alexander:</b> Writing – original draft.</p><p>The authors declared no conflict of interest.</p>","PeriodicalId":11954,"journal":{"name":"European Journal of Neurology","volume":"32 1","pages":""},"PeriodicalIF":4.5000,"publicationDate":"2024-12-18","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://onlinelibrary.wiley.com/doi/epdf/10.1111/ene.16565","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"European Journal of Neurology","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ene.16565","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"CLINICAL NEUROLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

In this edition of the European Journal of Neurology, Braun et al. report results from a systematic literature review of publications reporting on autologous hematopoietic stem cell transplantation (HSCT) for multiple sclerosis (MS) undergoing progressive neurological decline in baseline without clinical relapses or decline between clinical relapses. They compared 665 patients with progressive multiple sclerosis (PMS) of which 74 were primary progressive MS (PPMS) defined as PMS from diagnosis and 591 with secondary progressive MS (SPMS) defined as PMS after an initial relapsing–remitting course. As controls they used 647 patients with RRMS defined as a relapsing–remitting course with stable neurological disability between relapses [1].

There are 16 disease modifying therapies (DMTs) approved by the Food and Drug Administration for RRMS. The effectiveness of DMTs for PMS is questionable or at best less clear. Multiple studies have demonstrated superiority of HSCT for RRMS including a large meta-analysis of 4831 patients [2] and a phase III randomized trial [3]. Because an effective therapy is needed for PMS, Braun et al. summarized the published outcome of HSCT for PMS. They found highly variable results in PMS patients in terms of achieving progression-free survival and no evidence of disease activity (NEDA-3), suggesting that HSCT does not halt progression in this patient cohort but may provide clinical benefit in selected patients.

RRMS is a dynamic and repetitive immune mediated breakdown in the blood–brain barrier, extravasation of immune cells, and macrophage stripping of myelin followed healing of the blood–brain barrier, remyelination and repair [4]. Neuronal damage starts during RRMS and becomes the predominate pathophysiology during SPMS [5]. PPMS is predominately neuronal degenerative from onset [6]. For this reason, immune based therapies including all DMTs and autologous HSCT are most effective in RRMS but of limited value for PMS (PPMS or SPMS) [6]. During the transition from predominately inflammatory RRMS into late SPMS, patients transition through a stage of SPMS with residual smoldering inflammation [7]. It is during this stage that immune based therapies such as HSCT are still of benefit, albeit to a lesser amount. On this background, recent guidelines and recommendations from the European Group for Blood and Marrow Transplantation (EBMT) Autoimmune Diseases Working Party (ADWP) and the Joint Accreditation Committee of EBMT and the International Society for Cellular Therapy (ISCT) (JACIE) suggest HSCT as standard indication in patients with active relapsing–remitting MS failing DMTs, and a clinical option in patients with progressive MS with active inflammatory component, but generally not in patients with progressive MS without active inflammatory component [8].

Identifying subsets of PMS that may still benefit from HSCT is essential. Two such subsets are active SPMS and potentially those with progression independent of relapse activity (PIRA). SPMS may be divided into active SPMS and non-active SPMS [9]. Non-active SPMS is quiescent in terms of relapses and new magnetic resonance imaging (MRI) lesions [8]. Active SPMS manifests a clinical relapse or a new MRI lesion over the prior year [8]. Using a non-myeloablative HSCT regimen of cyclophosphamide and anti-thymocyte globulin (ATG), the neurological disability of patients with active SPMS improved [10]. RRMS and active SPMS had a sustained mean decline in Expanded Disability Status Scale of >1.0 and >0.5 points, respectively, after HSCT [9]. Non-active SPMS did not improve [10]. The extent to which active neuronal inflammation at baseline had an influence on the reported results of Braun et al. in PMS patients remains unclear, as no data on this subject were included. Nevertheless, the available data demonstrating that PPMS patients benefited less than SPMS and particularly RRMS patients clearly indicate that the less inflammation the lower the response to HSCT.

Patients treated with anti-B cell monotherapy may have slow silent accumulation of disability without clinical relapses or MRI changes, a phenomenon termed PIRA [11]. To ensure that MRI imaging was included in truly defining PIRA, recently the term PIRMA (progression independent of relapse and MRI activity) was introduced [12]. Relapse-independent accumulation of disability has been documented for patients on natalizumab [13]. Recently more specialized MRI analysis has documented persistent paramagnetic rim lesions in patients on ocrelizumab [14]. Such studies suggest that PIRMA arises from incomplete treatment of smoldering inflammation not evident by gross clinical relapse or on routine MRI. MRI paramagnetic rim lesions are associated with PIRMA and arise from and are consistent with persistent low-grade inflammation, free radical generation, and iron deposition in activated microglia and immune cells located on the periphery of chronic active lesions.

Why is PIRMA so prevalent for patients on anti-CD20 B cell monoclonal therapy? B cells play a role in MS and traffic into and out of acute lesions and are only a small percentage of immune cells within chronic active lesions [15]. It is therefore possible that B cell directed therapies do not cover smoldering low-grade T cell mediated inflammation. Elimination of B cell activity but unchecked T cell reactivity may lead to no noticeable clinical attacks and no new MRI lesions on routine MRI but slow progression of disability, that is, PIRMA. Recently we have performed HSCT with a non-myeloablative regimen using cyclophosphamide and ATG in several patients on anti-CD20 monoclonal antibody therapy with PIRMA. All had improvement in Expanded Disability Status Scale and reversal of symptoms after HSCT (unpublished), suggesting that the mechanisms of HSCT would go beyond a single cell line effect (T or B cell directed).

In conclusion, the report by Braun et al. confirms previous findings demonstrating better outcomes in RRMS compared to SPMS and PPMS patients and suggests that central nervous system inflammation is a predictor for response. While HSCT is usually ineffective in late SPMS (non-active SPMS) or PPMS, there is early evidence that some types of PMS such as active SPMS and PIRMA while on anti-CD20 B cell therapy do benefit from HSCT probably because of continued smoldering inflammation. Further studies are required in MS to clearly demonstrate the efficacy of HSCT in reducing PIRMA, and these investigations should use harmonized definitions of PIRMA [16]. These aspects should be considered when selecting patients for HSCT in addition to failure of available DMTs.

Richard K. Burt: Writing – original draft. Tobias Alexander: Writing – original draft.

The authors declared no conflict of interest.

造血干细胞移植治疗多发性硬化症:无炎症,无反应。
在这一期的《欧洲神经病学杂志》上,Braun等人报道了一项系统文献综述的结果,该文献综述报道了自体造血干细胞移植(HSCT)治疗多发性硬化症(MS)的结果,这些多发性硬化症(MS)在基线时出现进行性神经功能衰退,无临床复发或在临床复发之间出现衰退。他们比较了665例进行性多发性硬化症(PMS)患者,其中74例为原发性进行性多发性硬化症(PPMS),从诊断开始定义为PMS, 591例为继发性进行性多发性硬化症(SPMS),定义为初始复发缓解期后的PMS。作为对照,他们使用了647例RRMS患者,RRMS定义为复发-缓解病程,在两次复发之间伴有稳定的神经功能障碍。美国食品和药物管理局批准了16种用于RRMS的疾病修饰疗法(DMTs)。dmt治疗经前症候群的有效性值得怀疑,或者至少不太清楚。多项研究已经证明了HSCT治疗RRMS的优越性,包括一项4831例患者的大型荟萃分析和一项III期随机试验[3]。由于经前症候群需要一种有效的治疗方法,Braun等人总结了经前症候群HSCT治疗的已发表结果。他们发现PMS患者在实现无进展生存和无疾病活动证据(NEDA-3)方面的结果变化很大,这表明HSCT不能阻止该患者队列的进展,但可能为选定的患者提供临床益处。RRMS是一种动态的、重复的免疫介导的血脑屏障破坏、免疫细胞外渗和巨噬细胞剥离髓磷脂,随后是血脑屏障愈合、髓鞘再生和bbb修复。神经元损伤开始于RRMS期间,并成为SPMS[5]期间的主要病理生理。从发病开始,PPMS主要是神经元变性。因此,包括所有dmt和自体造血干细胞移植在内的基于免疫的治疗方法对RRMS最有效,但对PMS (PPMS或SPMS) bb0的价值有限。在以炎症为主的RRMS向晚期SPMS过渡的过程中,患者会经历一个伴有残余阴燃炎症的SPMS阶段。正是在这个阶段,基于免疫的疗法,如造血干细胞移植,仍然是有益的,尽管数量较少。在此背景下,最近来自欧洲血液和骨髓移植组织(EBMT)自身免疫性疾病工作组(ADWP)以及EBMT和国际细胞治疗学会(ISCT)联合认证委员会(JACIE)的指南和建议,建议HSCT作为活动性复发-缓解型MS失败dmt患者的标准适应症,以及具有活动性炎症成分的进行性MS患者的临床选择。但在没有活跃炎症成分[8]的进展性MS患者中通常不存在。鉴别仍可从HSCT中获益的经前症候群是必要的。两个这样的亚群是活跃的SPMS和潜在的独立于复发活动的进展(PIRA)。SPMS可分为主动SPMS和非主动SPMS[9]。在复发和新的磁共振成像(MRI)病变[8]方面,非活动性SPMS是静止的。活动性SPMS表现为临床复发或在前一年出现新的MRI病变。使用环磷酰胺和抗胸腺细胞球蛋白(ATG)的非清髓性造血干细胞移植方案,活动性SPMS患者的神经功能障碍得到改善。在HSCT后,RRMS和活跃SPMS在扩展残疾状态量表上的平均持续下降分别为1.0和0.5分。非活性SPMS对b[10]无改善作用。Braun等人在经前症候群患者中报道的基线时活跃的神经元炎症对结果的影响程度尚不清楚,因为没有纳入该主题的数据。然而,现有数据表明,PPMS患者的获益低于SPMS,尤其是RRMS患者,这清楚地表明炎症越少,对HSCT的反应越低。接受抗b细胞单药治疗的患者可能会有缓慢的无声的残疾积累,没有临床复发或MRI改变,这种现象称为PIRA[11]。为了确保将MRI成像纳入PIRA的真正定义,最近引入了术语PIRMA(独立于复发和MRI活动的进展)。在使用natalizumab的患者中,已记录了不依赖复发的残疾积累。最近,更专业的MRI分析记录了使用ocrelizumab的患者持续的顺磁性边缘病变。这些研究表明,PIRMA是由未完全治疗的阴燃性炎症引起的,没有明显的临床复发或常规MRI检查。MRI顺磁边缘病变与PIRMA相关,起源于慢性活动性病变周围激活的小胶质细胞和免疫细胞中持续的低度炎症、自由基生成和铁沉积,并与之一致。 为什么PIRMA在接受抗cd20 B细胞单克隆治疗的患者中如此普遍?B细胞在MS和进出急性病变中发挥作用,在慢性活动性病变[15]中仅占很小比例的免疫细胞。因此,B细胞定向治疗可能不包括阴燃的低级别T细胞介导的炎症。消除B细胞活性而抑制T细胞反应可能导致不明显的临床发作,常规MRI检查无新的MRI病变,但残疾进展缓慢,即PIRMA。最近,我们对几例使用PIRMA抗cd20单克隆抗体治疗的患者进行了非清髓方案的HSCT,使用环磷酰胺和ATG。所有患者在HSCT后扩展残疾状态量表均有改善,症状逆转(未发表),这表明HSCT的机制将超越单细胞系效应(T或B细胞导向)。总之,Braun等人的报告证实了先前的研究结果,RRMS患者比SPMS和PPMS患者的预后更好,并提示中枢神经系统炎症是反应的预测因子。虽然HSCT通常对晚期SPMS(非活动性SPMS)或PPMS无效,但早期证据表明,某些类型的PMS(如活动性SPMS和PIRMA)在接受抗cd20 B细胞治疗时确实受益于HSCT,可能是因为持续的阴燃炎症。MS需要进一步的研究来明确证明HSCT在降低PIRMA方面的有效性,这些研究应该使用统一的PIRMA bbb定义。在选择HSCT患者时,除了考虑现有dmt的失败外,还应考虑这些方面。理查德·k·伯特:写作——原稿。托拜厄斯·亚历山大:写作——原稿。作者声明没有利益冲突。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
European Journal of Neurology
European Journal of Neurology 医学-临床神经学
CiteScore
9.70
自引率
2.00%
发文量
418
审稿时长
1 months
期刊介绍: The European Journal of Neurology is the official journal of the European Academy of Neurology and covers all areas of clinical and basic research in neurology, including pre-clinical research of immediate translational value for new potential treatments. Emphasis is placed on major diseases of large clinical and socio-economic importance (dementia, stroke, epilepsy, headache, multiple sclerosis, movement disorders, and infectious diseases).
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信